The veterinary tuberculosis (TB) vaccine market is influenced by several factors driving its dynamics. One of the key factors is the rising prevalence of bovine tuberculosis, which poses significant economic and public health challenges. Increasing efforts to control and eradicate TB in livestock, particularly cattle, drive the demand for effective vaccines. Governments and regulatory bodies in many countries are implementing stringent regulations to ensure the safety of animal products, further fueling the demand for TB vaccines in veterinary settings. Additionally, advancements in veterinary medicine and research contribute to the development of novel vaccine candidates. Collaborative initiatives between research institutions, government agencies, and vaccine manufacturers facilitate the production and distribution of veterinary TB vaccines. However, challenges such as the need for improved diagnostics and limited awareness about TB control measures in certain regions can hinder market growth. Nonetheless, the veterinary TB vaccine market is expected to witness steady growth due to the increasing focus on animal health and the demand for safe and sustainable food production practices.
Global Veterinary Tuberculosis Vaccine Market is estimated to be valued at US$ 50.89 Mn in 2022 and is expected to exhibit a CAGR of 3.2% over the forecast period (2022-2030).
Major Players in the Veterinary Tuberculosis (TB) Vaccine Industry:
Merck KGaA
Merck KGaA, also known as Merck Group, was founded in 1668 and is headquartered in Darmstadt, Germany. It is a leading multinational pharmaceutical and life sciences company. Merck operates in more than 120 countries worldwide, providing a wide range of healthcare products and solutions.